Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.
作者信息
Maeda T, Hiura A, Uehara J, Toyoshima R, Nakagawa T, Yoshino K
机构信息
Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
出版信息
Br J Dermatol. 2022 Mar;186(3):587-588. doi: 10.1111/bjd.20879. Epub 2021 Dec 21.
PMID:34747503
Abstract
摘要
Zotero 插件